288 Cost-Effectiveness of Sacral Neuromodulation in Refractory Overactive Bladder a Canadian Perspective

Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System

“…When positioned earlier than BoNT/A in the treatment pathway, SNM demonstrated to be cost effective (ICUR < 40.000 €/QALY) after 3 years already (€21,258.72/QALY), becoming dominant (both less costly-€333.22 saved-and more effective-0.59 QALY gained) at 10 years. Results from our analysis are comparable with those of other studies conducted in European Countries [6][7][8] as well as in the USA [24] and Canada [25], all of them suggesting the medium-and long-term value-for-money of a therapeutic pathway starting with SNM. In 2010, Siddiqui et al [26] did not reach the same conclusion, being early SNM not cost effective against the willingness-to-pay thresholds assumed to be relevant for the USA, namely $50,000 and $100,000 per QALY gained.…”